NBIX · Neurocrine Biosciences, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on NBIX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About NBIX · Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Live Quote
HOLD (score +3) · 12-1 mom 21.3% · RSI 57 · above_both · -3.5% from high
Targets blend Wall Street consensus (28 analysts: low $144.00 / mean $194.38 / high $250.65) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The investigation found 11 Form-4 filings in 14 days but almost entirely RSU/option grants and pre-planned (10b5-1) option exercises — not open-market purchases. CEO Pops exercised near-expiring options ($47.89 strike, expiring May 20, 2026) and sold via a Feb. 13, 2026 10b5-1 plan; CSO Onyia similarly exercised at $84.74 and sold via a Feb. 25 plan. No genuine open-market insider buy (P code) exists in the cluster. The stock is strong fundamentally — Q1 EPS beat ($1.94 vs $1.70 est), forward P/E of only ~12.5x on 23% earnings growth, ~$590M FCF, near-zero net debt — but sits at a 52-week high with elevated RSI (70) and no identifiable mispricing or near-term catalyst that would create asymmetric upside from here.
Recent news from TradeBytes mentioning NBIX
Articles from the sister news site that name this ticker. Independent of the AI pipeline's research.